Year: 2016
Type: article
Abstract: Uveitis is an important cause of vision loss worldwide due to its sight-threatening complications, especially cystoid macular edema, as well as choroidal neovascularization, macular ischemia, cataract, and glaucoma. Systemic corticosteroids are the mainstay of therapy for noninfectious posterior uveitis; however, various systemic side effects can occur. Intravitreal medication achieves a therapeutic level in the vitreous while minimizing systemic complications and is thus used as an exciting alternative. Corticosteroids, antivascular endothelial growth factors, immunomodulators such as methotrexate and sirolimus, and nonsteroidal anti-inflammatory drugs are currently available for intravitreal therapy. This article reviews the existing literature for efficacy and safety of these various options for intravitreal drug therapy for the management of noninfectious uveitis (mainly intermediate, posterior, and panuveitis).
Source: Clinical ophthalmology
DOI: 10.2147/opth.s89341
Institutions: National University of Singapore, University of Nebraska Medical Center, University of Washington, L V Prasad Eye Institute, Post Graduate Institute of Medical Education and Research, Nanyang Technological University, National Health Service, Moorfields Eye Hospital NHS Foundation Trust, Moorfields Eye Hospital, Tan Tock Seng Hospital, National Healthcare Group
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,320
Award: G3703780889
OpenAlex ID: W2531185339